Anakinra in Previously Untreated Chronic Lymphocytic Leukemia Patients
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a phase I trial of the IL-1 receptor antagonist anakinra in chronic lymphocytic
leukemia patients who are predicted to eventually require first-line therapy based on
conventional clinical criteria. Three groups of 4 patients will be injected subcutaneously
with either 100 mg daily or 100 mg twice daily or 200 mg twice daily for 7 cycles of 4 weeks
each to determine the dose-limiting toxicity of anakinra in this population. Clinical
responses will be determined by conventional IWCLL criteria. It is hoped anakinra will
prevent disease progression with little toxicity. The study is anticipated to be completed
within a year.